Physicians' Academy for Cardiovascular Education

Epigenetics in CKD & CVD: A potential breakthrough therapy?

Meeting report with video, highlights and slides of PACE-CME symposium held during ERA-EDTA 2018 in Copenhagen on the potential role of epigenetics in patients with CKD, CVD and diabetes

A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA
Kalantar shares data that suggest that epigenetic modification with the BET inhibitor apabetalone may improve factors involved in the pathogenesis of CKD, including alkaline phosphatase.

Kalantar shares data that suggest that epigenetic modification with the BET inhibitor apabetalone may improve factors involved in the pathogenesis of CKD, including alkaline phosphatase.

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Louise Nordfors - Stockholm, Sweden
Louise Nordfors describes several epigenetic mechanisms that have been described to be dysregulated in human disease and the rationale for BET protein inhibition to treat CV and renal disease.

Louise Nordfors describes several epigenetic mechanisms that have been described to be dysregulated in human disease and the rationale for BET protein inhibition to treat CV and renal disease.

Slides: A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

Presentation prof Kamyar Kalantar-Zadeh

Slides (presentation) - May 25, 2018 - ERA-EDTA 2018, Copenhagen - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA
This lecture by prof. Kamyar Kalantar-Zadehwas part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA 2018 in Copenhagen

Slides as educational service to PACE members and meeting participants

Slides: Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

Presentation Dr. Louise Nordfors

Slides (presentation) - May 25, 2018 - ERA-EDTA 2018, Copenhagen - Dr Louise Nordfors - Stockholm, Sweden
This lecture by dr. Louise Nordfors was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy?' held at ERA-EDTA 2018 in Copenhagen

Slides as educational service to PACE members and meeting participants

Slides: Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

Presentation prof. Erik Stroes

Slides (presentation) - May 25, 2018 - ERA-EDTA 2018, Copenhagen - Prof. Erik Stroes - Amsterdam, NL
This lecture by prof Erik Stroes was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy?' held at ERA-EDTA 2018 in Copenhagen

Slides as educational service to PACE members and meeting participants

Epigenetics in CKD & CVD: A potential breakthrough therapy?
Epigenetics in CKD & CVD: A potential breakthrough therapy?